Solid tumour CAR-T cells engineered with fusion proteins targeting PD-L1 for localized IL-12 delivery
{{output}}
Chimeric antigen receptor (CAR)-T cell efficacy in solid tumours is limited due in part to the immunosuppressive tumour microenvironment (TME). To improve antitumour responses, we hypothesized that enabling CAR-T cells to secrete bifunctional fusion proteins c... ...
